Login to Your Account

Chinese CAR T firm ICT licenses Vericel's cell therapy platform for Asia

By Shannon Ellis
Staff Writer

Wednesday, May 17, 2017

SHANGHAI – Innovative Cellular Therapeutics Co. Ltd. (ICT), of Shanghai, a leader among China's pack of emerging CAR T oncology companies, has struck a partnership deal with Vericel Corp., the first biotech to receive FDA approval for a tissue-engineered autologous cell scaffold.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription